Replies to post #2082 on Teva Pharmaceutical Industries Ltd (TEVA)

[DewDiligence]

Gal cites the following risks to Teva: deterioration of Copaxone revenue due to rapid adoption of Tysabri in 2008 or rapid success of a Paragraph IV challenge on Copaxone

At this point, the latter is a bigger problem than the former, IMO.

I wonder why Gal doesn’t say anything about Truvada.